Acute promyelocytic leukemia: A population-based study on incidence and survival in the United States, 1975-2008

Cancer

Volumn 118, Issue 23, 2012, Pages 5811-5818

  Chen, Yiming ^a   Kantarjian, Hagop ^a   Wang, Haijun ^b   Cortes, Jorge ^a   Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

APL; ATO; ATRA; incidence; survival

Indexed keywords

ANTHRACYCLINE; CYTARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; RETINOIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; EVENT FREE SURVIVAL; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SCHOOL CHILD; STEM CELL TRANSPLANTATION; SURVIVAL TIME; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARSENICALS; FEMALE; HUMANS; INCIDENCE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; OXIDES; SEER PROGRAM; TIME FACTORS; TRETINOIN; UNITED STATES;

EID: 84869502214     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27623     Document Type: Article

References (40)

1. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998; 339: 1341-1348. (Pubitemid 28509343)
2. Yamamoto JF, Goodman MT,. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control. 2008; 19: 379-390.
3. de The H, Chen Z,. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010; 10: 775-783.
4. Licht JD,. Acute promyelocytic leukemia-weapons of mass differentiation. N Engl J Med. 2009; 360: 928-930.
5. Sanz MA, Lo-Coco F,. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol. 2011; 29: 495-503.
6. Nowak D, Stewart D, Koeffler HP,. Differentiation therapy of leukemia: 3 decades of development. Blood. 2009; 113: 3655-3665.
7. Ablain J, de The H,. Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood. 2011; 117: 5795-5802.
8. Tallman MS, Nabhan C, Feusner JH, Rowe JM,. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002; 99: 759-767. (Pubitemid 34525534)
9. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997; 337: 1021-1028. (Pubitemid 27430519)
10. Kantarjian HM, Keating MJ, Walters RS, et al. Acute promyelocytic leukemia. M.D. Anderson Hospital experience. Am J Med. 1986; 80: 789-797. (Pubitemid 16033697)
11. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988; 72: 567-572.
12. Sun HD, Ma L, Hu X-C,. Ai-Ling 1 treated 32 cases of acute promyelocytic leukemia. Chin J Integrat Chin Western Med. 1992; 12: 170-172.
13. Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997; 89: 3345-3353. (Pubitemid 27229821)
14. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997; 89: 3354-3360.
15. Zhang P, Wang SY, Hu XH,. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol. 1996; 17: 58-62.
16. Warrell RP Jr, Frankel SR, Miller WH Jr, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991; 324: 1385-1393.
17. Frankel SR, Eardley A, Heller G, et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med. 1994; 120: 278-286. (Pubitemid 24050023)
18. Camacho LH, Soignet SL, Chanel S, et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol. 2000; 18: 2620-2625. (Pubitemid 30432530)
19. US Department of Health and Human Services. Archive. Available at: http://archive.hhs.gov/news/press/1995pres/951128a. html. Accessed June 22, 2011.
20. Antman KH,. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist. 2001; 6 (suppl 2): 1-2. (Pubitemid 32405842)
21. Center for International Blood and Marrow Transplant Research. Available at: http://www.cibmtr.org/pages/index.aspx. Accessed June 22, 2011.
22. National Cancer Institute. The Surveillance, Epidemiology and End Results Program. Available at: http://seer.cancer.gov/. Accessed June 22, 2011.
23. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21: 4642-4649. (Pubitemid 46594039)
24. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M,. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007; 25: 1993-1999. (Pubitemid 46972782)
25. Brenner H, Arndt V,. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. J Clin Oncol. 2005; 23: 441-447. (Pubitemid 46224219)
26. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009; 301: 2349-2361.
27. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010; 116: 3751-3757.
28. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002; 100: 4298-4302. (Pubitemid 36001941)
29. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001; 19: 3852-3860. (Pubitemid 32880064)
30. Zheng X, Seshire A, Ruster B, et al. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica. 2007; 92: 323-331. (Pubitemid 350143541)
31. Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010; 28: 3866-3871.
32. Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006; 107: 2627-2632.
33. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006; 107: 3469-3473.
34. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009; 27: 504-510.
35. Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011; 118: 1248-1254.
36. Park JH, Tallman MS,. Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy. Oncology (Williston Park). 2011; 25: 733-741.
37. Ravandi F,. Acute promyelocytic leukemia can be treated successfully without cytotoxic chemotherapy. Oncology (Williston Park). 2011; 25: 741-743.
38. Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009; 106: 3342-3347.
39. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999; 94: 3315-3324. (Pubitemid 29536124)
40. Ghavamzadeh A, Alimoghaddam K, Rostami S, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011; 29: 2753-2757.